论文部分内容阅读
作者用B群Ⅲ型链球菌(Ⅲ型GBS)作为模型菌,对静脉注射免疫球蛋白制剂(瑞士红十字会免疫球蛋白,SRK-Ig)作体内外抗菌活性的研究,试验表明SRK-Ig可增强人体中性白细胞对Ⅲ型GBS的吞噬和杀伤作用。在B群链球菌感染的新生期败血症动物模型实验中表明,SRK-Ig具有一定的抗菌活性,对某些细菌性感染有预防或治疗作用。Ⅲ型GBS一般能引起新生儿败血症和脑膜炎,尽管积极治疗,发病率和死亡率仍极高。在对GBS有效的吞噬和杀伤中,调理抗体和补体是必不可少的。本试验利用一种中性白细胞介导的杀菌性检测法和感染GBS的大白鼠模型,分别在体内外评价其功能活性。
In this study, we investigated the antibacterial activities of intravenous immunoglobulin preparations (Swiss Red Cross immunoglobulin, SRK-Ig) in vitro and in vivo using Group B Streptococcus group Ⅲ (GBS Ⅲ) as a model strain. The results showed that SRK-Ig Can enhance the phagocytic and cytotoxic effects of human neutrophils on type III GBS. In group B streptococcal neonatal sepsis animal model experiments show that, SRK-Ig has some antibacterial activity, for some bacterial infections have a preventive or therapeutic effect. Type III GBS generally causes neonatal sepsis and meningitis, and despite aggressive treatment, morbidity and mortality are still extremely high. In the phagocytosis and killing of GBS, the regulation of antibodies and complement is essential. In this experiment, a neutrophil-mediated bactericidal assay and a rat model of GBS infection were used to evaluate their functional activity in vivo and in vitro, respectively.